Lercanidipina Eg

Lercanidipine Hydrochloride, the active ingredient in Lercanidipina Eg, is a calcium channel blocker presented as an oral tablet for oral use. It treats hypertension in adult patients.

GNH USA supplies Lercanidipina Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is a calcium channel blocker used to manage high blood pressure and related conditions.

- Essential hypertension: lowers systolic and diastolic blood pressure to target levels - Isolated systolic hypertension: reduces elevated systolic pressure, especially in elderly patients - Hypertension in patients with diabetes: assists in achieving recommended blood pressure goals while maintaining glycemic control

Lercanidipine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity, often transient - Flushing: warmth and redness, typically resolves with continued therapy - Peripheral edema: swelling of ankles or lower limbs - Dizziness or light‑headedness: especially after standing - Tachycardia: increased heart rate without other cardiac symptoms - Palpitations: sensation of irregular heartbeat

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat requiring immediate medical attention - Severe hypotension: marked drop in blood pressure causing faintness or shock - Myocardial infarction: rare occurrence of heart attack symptoms - Hepatic dysfunction: abnormal liver enzymes or hepatitis - Severe allergic reactions: rash, itching, or anaphylaxis - Stevens‑Johnson syndrome: rare skin blistering disorder

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Monitor blood pressure: ensure adequate control and avoid excessive hypotension - Assess for peripheral edema: consider dose adjustment or diuretic therapy if swelling develops - Caution in hepatic impairment: reduced metabolism may increase drug exposure - Avoid abrupt discontinuation: tapering may be needed to prevent rebound hypertension - Review concomitant CYP3A4 inhibitors: dose may require adjustment - Store at room temperature: keep in the original container, protect from moisture and direct sunlight

Lercanidipine can interact with several medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise plasma concentrations and increase adverse effects - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may lower drug levels, reducing antihypertensive effect - Concurrent use with other potent antihypertensives (e.g., ACE inhibitors, other calcium channel blockers): risk of excessive blood pressure reduction

Moderate Interactions (Monitor Closely):\n- Simvastatin or other statins metabolized by CYP3A4: increased risk of myopathy - Grapefruit juice: can elevate lercanidipine concentrations - Diuretics: may enhance hypotensive response, requiring closer blood pressure monitoring